Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016287 | 1.00 | CA12 (0.45) | CA12CA1CA2TYRCA7 | |
| SCHEMBL20027243 | 0.90 | NPSR1 (0.47) | CA12CA1CA2TYRCA7 | |
| SCHEMBL22870340 | 0.87 | CA12 (0.45) | CA12CA1CA2TYRCA7 | |
| SCHEMBL29088414 | 0.87 | CA12 (0.45) | CA12CA1CA2TYRCA7 | |
| SCHEMBL22870156 | 0.84 | ALDH1A1 (0.46) | CA12CA1CA2TYRCA7 | |
| SCHEMBL29088421 | 0.84 | ALDH1A1 (0.46) | CA12CA1CA2TYRCA7 | |
| SCHEMBL4119043 | 0.83 | KMT2A (0.45) | DAOKMT2AMAPK1ALDH1A1MAPT | |
| SCHEMBL4119039 | 0.83 | KMT2A (0.45) | DAOKMT2AMAPK1ALDH1A1MAPT | |
| SCHEMBL24931157 | 0.81 | CA12 (0.41) | CA12CA1CA2TYRCA7 | |
| SCHEMBL22870380 | 0.80 | CA12 (0.40) | CA12CA1CA2TYRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086098-B1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-6660728-B2 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH AND GENENTECH, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6566366-B1 | For therapy of tumor growth, osteoporosis, inflammation and cardiovascular disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-20 | — | — | US | disclosed |
| EP-1086098-A1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2001-03-28 | — | — | EP | disclosed |
| EP-0960882-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999059992-A1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | ASGR1, PTMS, B3GNT2 | CA12 4093/4885CA1 3670/4885CA2 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.